1-thia-5-aza-bicyclo (4.2.0) Octane Ring Containing (including Dehydrogenated) (e.g., Cephalosporins, Etc.) Patents (Class 514/200)
  • Patent number: 10239890
    Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: March 26, 2019
    Assignee: Gladius Pharmaceuticals Corporation
    Inventors: Larry Sutton, Sophia Yu
  • Patent number: 9975905
    Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making betalactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: May 22, 2018
    Assignee: Gladius Pharmaceuticals Corporation
    Inventors: Larry D. Sutton, Sophia Yu
  • Patent number: 9920003
    Abstract: Sugar-derived tetrol, non-ionic amphiphilic amine-esters are prepared facilely and efficaciously in a few steps. The process is initiated by the esterification of a sugar-derived tetrol with a fatty acid chloride, then, undergoing triflate esterification followed by nucleophilic displacement of the aforementioned hydrophilic amine. Each synthetic pathway is efficient and affords modest to high yields of target amphiphiles, which are valorized as practicable surfactant surrogates to petroleum incumbents.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: March 20, 2018
    Assignee: Archer Daniels Midland Company
    Inventor: Kenneth Stensrud
  • Patent number: 9862729
    Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition. Additionally provided are pharmaceutical compositions for treatment or prevention of bacterial infections and methods of treatment of such infections.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: January 9, 2018
    Assignee: GLADIUS PHARMACEUTICALS CORPORATION
    Inventors: Larry Sutton, Sophia Yu
  • Patent number: 9566337
    Abstract: The present invention provides a pharmaceutical formulation prepared as dry syrups representing mere powder mixtures of beta-lactam antibiotics as active pharmaceutical ingredients and excipients without applying any other process steps than simple mixing of dry powder, whereby the pharmaceutical formulation combines two essential properties for processability and dosability: good flowability and high stability against segregation.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: February 14, 2017
    Assignee: SANDOZ AG
    Inventors: Stefan Scheler, Johannes Raneburger, Franz Xaver Schwarz, Florian Kern
  • Patent number: 9532944
    Abstract: Described herein are methods and pharmaceutical formulations for improving ocular discomfort.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: January 3, 2017
    Assignee: OYSTER POINT PHARMA, INC.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Patent number: 9381227
    Abstract: A system, including methods and compositions, for treatment of ischemia.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: July 5, 2016
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Roger P. Simon, Zhi-Gang Xiong
  • Publication number: 20150111834
    Abstract: The disclosure provides a recipe for in-situ gel, formed by dissolving at least one polymer and at least one gel prevention agent in a polar solvent to form a solution and placing the solution in a condition for in-situ forming gels. The disclosure also provides an implant and a drug delivery system formed by the recipe.
    Type: Application
    Filed: September 17, 2014
    Publication date: April 23, 2015
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Felice CHENG, Maggie J.M. LU, Yi-Ju KO, Min-Ying LIN, Shuen-Hsiang CHOU
  • Patent number: 8968753
    Abstract: Pharmaceutical compositions can include ceftolozane lyophilized in the absence of tazobactam.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: March 3, 2015
    Assignee: Calixa Therapeutics, Inc.
    Inventors: Joseph Terracciano, Nicole Miller Damour, Chun Jiang, Giovanni Fogliato, Giuseppe Alessandro Donadelli, Dario Resemini
  • Patent number: 8956653
    Abstract: The present invention relates to a process for preparing effervescent dosage forms comprising at least one antibiotic of cephalosporin group. The present invention also relates to effervescent formulations and preparations comprising antibiotics of second generation cephalosporin.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: February 17, 2015
    Inventor: Mahmut Bilgic
  • Publication number: 20150031658
    Abstract: This invention relates generally to the discovery of a method of inhibiting, preventing or treating bacterial infections. The invention also relates to a method of inhibiting bacterial capsule biogenesis.
    Type: Application
    Filed: October 15, 2014
    Publication date: January 29, 2015
    Inventors: Patrick C. Seed, Carlos C. Goller, Apurba Dutta, Brooks Maki, Frank Schoenen, James Noah, Lucile White
  • Publication number: 20150004216
    Abstract: A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the film layer by any desired method. The composition of the powder matrix is varied to alter the dissolution rate of the medicant, the adhesion of the medicant composition, and other physical properties of the powder matrix. The powder matrix layer can be cured.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 1, 2015
    Inventor: Robert Steven Davidson
  • Publication number: 20140371194
    Abstract: This invention relates generally to the discovery of a method of inhibiting, preventing or treating bacterial infections. The invention also relates to a method of inhibiting bacterial capsule biogenesis.
    Type: Application
    Filed: June 16, 2014
    Publication date: December 18, 2014
    Inventors: Patrick C. Seed, Carlos C. Goller, Apurba Dutta, Brooks Maki, Frank Schoenen, James Noah, Lucile White
  • Patent number: 8911765
    Abstract: A biodegradable, flexible covering for a breast implant is provided which comprises one or more biodegradable polymer layers dimensioned and shaped to cover at least a portion of the breast implant. The implant can be inserted into an opening of the covering immediately prior to surgery, but alternate configurations and times of insertion are contemplated as well as open or sheet type devices. The coverings can optionally contain one or more drugs for delivery at the surgical site, particularly for treating or preventing infection, pain, inflammation, capsular contracture, scarring or other complications associated with breast augmentation or breast reconstruction.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: December 16, 2014
    Assignee: Tyrx, Inc.
    Inventors: Arikha Moses, Satish Pulapura, Qing Ge, Sarita Nethula, Irene Shatova, Archana Rajaram
  • Patent number: 8883772
    Abstract: Broad spectrum beta-lactamase inhibitors. Certain inhibitors also exhibit potent antibiotic activity in addition to beta-lactamase inhibition. Compounds of the invention are designed such that on cleavage of the beta-lactam ring reactive moieties are generated which can inactivate beta-lactamase. Compounds of the invention include those of formula: and pharmacologically acceptable salts thereof where variables Z, Y, M, y, n, R, R4, R5, R1 and R2 are as defined in the specification. M most generally represents a chemical moiety which is in conjugation with the nitrogen of the core beta-lactam ring system of the compound, such that one or more reactive species, e.g., electrophilic or nucleophilic sites are generated on modification of M which is initiated by cleavage of the beta-lactam ring. Also provided are methods of making beta-lactamase inhibitors and beta-lactam antibiotics exhibiting such inhibition.
    Type: Grant
    Filed: October 9, 2008
    Date of Patent: November 11, 2014
    Assignee: Sopharmia, Inc.
    Inventors: Larry Sutton, Sophia Yu
  • Publication number: 20140328896
    Abstract: Provided are methods and compositions for enhancing the gastrointestinal health of an animal in need thereof by administering a gastrointestinal health maintaining or improving amount of a composition comprising an effective amount of lactic acid. The administered composition may also comprise one or more prebiotic, probiotic, symbiotic, anti bacterial, or anti-diarrhea agents.
    Type: Application
    Filed: December 29, 2011
    Publication date: November 6, 2014
    Applicant: HILL'S PET NUTRITION, INC.
    Inventors: Dennis Jewll, Luis J. Montelongo, Sarah Martinez, Lynda Melendez
  • Publication number: 20140323391
    Abstract: Disclosed herein are biomarkers useful for identifying and/or classifying bacterial infections in a subject.
    Type: Application
    Filed: March 15, 2014
    Publication date: October 30, 2014
    Applicant: Duke University
    Inventors: Ephraim Tsalik, Vance Fowler, Christopher W. Woods, Joseph E. Lucas, Geoffrey S. Ginsburg, Sun Hee Ahn
  • Publication number: 20140315876
    Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.
    Type: Application
    Filed: March 12, 2014
    Publication date: October 23, 2014
    Inventors: Yu Gui Gu, Yong He, Ning Yin, Dylan C. Alexander, Jason B. Cross, Chester A. Metcalf, III
  • Patent number: 8865697
    Abstract: A solid DMSO solvate of a compound of formula (I) is described, which is a useful intermediate for preparing the broad spectrum antibiotics Ceftobiprole and Ceftobiprole Medocaril.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: October 21, 2014
    Assignee: Basilea Pharmaceutica AG
    Inventors: Marco Alpegiani, Walter Cabri, Markus Heubes, Davide Longoni, Michael Schleimer
  • Publication number: 20140221330
    Abstract: An objective of the present invention is to provide a novel NDM (New Delhi metallo-?-lactamase) inhibitor that functions as a drug for restoring the antibacterial activity of ?-lactam antibiotics that have been inactivated as a result of decomposition by NDM.
    Type: Application
    Filed: July 26, 2012
    Publication date: August 7, 2014
    Inventors: Akihiro Morinaka, Kazunori Maebashi, Takashi Ida, Muneo Hikida, Mototsugu Yamada, Takao Abe
  • Publication number: 20140221331
    Abstract: The present invention relates generally to methods and compounds for regulating the release of nitric oxide in the vicinity of biofilm-forming microorganisms to regulate programmed cell death in the microorganisms and thereby promote dispersal of microorganism from biofilms and/or inhibit biofilm formation or development. More particularly, the invention relates to the use of compounds to provide spatial and temporal control over nitric oxide release.
    Type: Application
    Filed: May 16, 2012
    Publication date: August 7, 2014
    Applicants: UNIVERSITY OF WOLLONGONG, NEWSOUTH INNOVATIONS PTY LIMITED
    Inventors: Nicolas Barraud, Bharat Gangadhar Kardak, Michael John Kelso, Staffan Kjelleberg, Scott Rice
  • Patent number: 8747900
    Abstract: The invention relates to a pharmaceutical composition comprising cefuroximaxetil and at least one carrageenan selected from the group consisting of ?-carrageenan, ?-carrageenan and -carrageenan. The invention furthermore relates to pellets, to a multiparticulate, pharmaceutical dosage form and to a novel crystalline modification of cefuroximaxetil.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: June 10, 2014
    Assignee: Gruenenthal GmbH
    Inventors: Iris Ziegler, Andreas Fischer
  • Patent number: 8734831
    Abstract: A method for manufacturing a porous ceramic scaffold having an organic/inorganic hybrid coating layer containing a bioactive factor includes (a) forming a porous ceramic scaffold; (b) mixing a silica xerogel and a physiologically active organic substance in a volumetric ratio ranging from 30:70 to 90:10 and treating by a sol gel method to prepare an organic/inorganic hybrid composite solution; (c) adding a bioactive factor to the organic/inorganic hybrid composite solution and agitating until gelation occurs; and (d) coating the porous ceramic scaffold with the organic/inorganic composite containing the bioactive factor added thereto. In accordance with the method, the porous ceramic scaffold may be uniformly coated with the organic/inorganic hybrid composite while maintaining an open pore structure, and stably discharge the bioactive factor over a long period of time.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: May 27, 2014
    Assignee: SNU R&DB Foundation
    Inventors: Hyoun-Ee Kim, Shin-Hee Jun, Eun-Jung Lee
  • Patent number: 8703757
    Abstract: The invention relates to a method to enhance germination of seeds and/or growth of plants or plant parts and/or plant yield by subjecting seeds to a pulsed radiofrequency electrical field (PRF).
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: April 22, 2014
    Assignee: UTOPS B.V.
    Inventors: Menno Emanuel Sluijter, Alexandre Jose Leonardo Teixeira
  • Publication number: 20140057829
    Abstract: Methods of diagnosing sepsis, severe sepsis, or septic shock and predicting prognosis in subjects with septic shock, based on levels of citrullinated histone H3 (Cit H3) in the subject, e.g., in a sample comprising serum (e.g., whole blood, serum, or plasma), cerebrospinal fluid, urine, saliva, or peritoneal fluid from the subject.
    Type: Application
    Filed: February 1, 2012
    Publication date: February 27, 2014
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Hasan B. Alam, Yongqing Li
  • Patent number: 8648065
    Abstract: An objective of the present invention is to provide a cefditoren pivoxil pharmaceutical preparation which can safely be administered to a patient and not only improves wettability of cefditoren pivoxil, but also further improves absorbability through the intestinal tracts by maintaining amorphous particles having a high oral absorbability in a liquid for a long period of time. The present invention is a pharmaceutical composition comprising amorphous cefditoren pivoxil and a sucrose fatty acid ester, which is obtainable by mixing or wet-granulating particles containing amorphous cefditoren pivoxil with the sucrose fatty acid ester while amorphous cefditoren pivoxil maintains its particle state.
    Type: Grant
    Filed: April 28, 2003
    Date of Patent: February 11, 2014
    Assignee: Meiji Seika Pharma Co., Ltd.
    Inventors: Yukiko Yokoi, Shigeru Chikase, Hiroyuki Yamaguchi
  • Publication number: 20130303504
    Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.
    Type: Application
    Filed: March 29, 2013
    Publication date: November 14, 2013
    Inventors: Yu Gui Gu, Yong He, Ning Yin, Dylan C. Alexander, Jason B. Cross, Chester A. Metcalf, III, Robert Busch
  • Publication number: 20130303437
    Abstract: The disclosure provides a molecular genetic approach of targeted mutagenesis and heterologous expression, coupled with in vitro and in vivo models of bacterial pathogenesis, to demonstrate that the S. aureus pigment is a virulence factor and potential novel target for antimicrobial therapy.
    Type: Application
    Filed: July 16, 2013
    Publication date: November 14, 2013
    Inventors: Victor NIZET, George Y. LIU
  • Publication number: 20130296290
    Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.
    Type: Application
    Filed: March 29, 2013
    Publication date: November 7, 2013
    Inventors: Yu Gui Gu, Yong He, Ning Yin, Dylan C. Alexander, Jason B. Cross, Chester A. Metcalf, III, Robert Busch
  • Publication number: 20130296293
    Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.
    Type: Application
    Filed: March 29, 2013
    Publication date: November 7, 2013
    Inventors: Yu Gui Gu, Yong He, Ning Yin, Dylan C. Alexander, Jason B. Cross, Chester A. Metcalf, III, Robert Busch
  • Publication number: 20130296292
    Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.
    Type: Application
    Filed: March 29, 2013
    Publication date: November 7, 2013
    Inventors: Yu Gui Gu, Yong He, Ning Yin, Dylan C. Alexander, Jason B. Cross, Chester A. Metcalf, III, Robert Busch
  • Publication number: 20130296291
    Abstract: ?-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D ?-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.
    Type: Application
    Filed: March 29, 2013
    Publication date: November 7, 2013
    Inventors: Yu Gui Gu, Yong He, Ning Yin, Dylan C. Alexander, Jason B. Cross, Chester A. Metcalf, III, Robert Busch
  • Publication number: 20130251790
    Abstract: The present invention provides a pharmaceutical composition comprising a low dose of zanamivir and a process for preparing the pharmaceutical composition comprising a low dose of zanamivir. The pharmaceutical composition comprising a low dose zanamivir may be used in the treatment and/or prophylaxis of influenza. The present invention also provides a method of treatment and/or prophylaxis of influenza which comprises administering a dry powder inhaler composition comprising a low dose zanamivir. The pharmaceutical composition of the present invention comprises zanamivir and one or more pharmaceutically acceptable excipients, wherein the total daily dose of the zanamivir is less than 10 mg, preferably for administration at least once a day, and preferably wherein the composition delivers from 3 mg to 8 mg of zanamivir per administered dose.
    Type: Application
    Filed: September 26, 2011
    Publication date: September 26, 2013
    Applicant: CIPLA LIMITED
    Inventors: Geena Malhotra, Shrinivas Madhukar Purandare
  • Publication number: 20130216609
    Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
    Type: Application
    Filed: March 21, 2013
    Publication date: August 22, 2013
    Applicants: The Regents of the University of California, Otonomy, Inc.
    Inventors: Otonomy, Inc., The Regents of the University of California
  • Publication number: 20130196900
    Abstract: The present invention provides compounds and compositions that enhance the innate immune system. The present invention comprises methods of preventing, treating or ameliorating an infectious disease comprising administering said compounds to a subject. The invention also comprises methods of formulation and administration of said compounds.
    Type: Application
    Filed: January 18, 2013
    Publication date: August 1, 2013
    Applicant: MONTANA STATE UNIVERSITY
    Inventor: MONTANA STATE UNIVERSITY
  • Publication number: 20130171210
    Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.
    Type: Application
    Filed: March 1, 2013
    Publication date: July 4, 2013
    Applicant: MICROBION CORPORATION
    Inventor: MICROBION CORPORATION
  • Patent number: 8461143
    Abstract: The present invention is directed to improved liquid antibiotic formulations. In some embodiments, the present invention is directed to a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v).
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: June 11, 2013
    Assignee: Taro Pharmaceuticals North America, Inc.
    Inventors: Shen Gao, Daniel A. Moros, Satish Asotra
  • Publication number: 20130131032
    Abstract: A method for improving sexual function is described. A mammal suffering from sexual dysfunction or otherwise in need of enhanced sexual function is administered a compound selected from those that are capable of inhibiting the activity of ?-lactams, penicillin-binding protein, carboxypeptidase. Such compounds, including particularly ?-lactam ring-containing compounds, can be used to formulate pharmaceutical formulations useful for improving sexual function.
    Type: Application
    Filed: January 25, 2013
    Publication date: May 23, 2013
    Applicant: Revaax Pharmaceuticals, LLC
    Inventor: Revaax Pharmaceuticals, LLC
  • Publication number: 20130131006
    Abstract: The present invention relates to a method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of AGE-albumin in cells of the mononuclear phagocyte system, to an AGE-albumin synthesis inhibitor, and to a pharmaceutical composition comprising the AGE-albumin synthesis inhibitor for preventing or treating degenerative disease and autoimmune disease. The AGE-albumin of the present invention is synthesized and secreted in human microglia or human macrophages in an Alzheimer's model, stroke model, Parkinson's disease model and rheumatoid arthritis model. The AGE-albumin synthesis and secretion are caused by oxidative stress. The expression of RAGE increases in first-order human neurons or cartilage cells to which AGE-albumin is administered, whereupon a MAPK signaling pathway is activated and the expression of Bax increases to induce an increase in calcium in mitochondria, thus finally inducing cell death.
    Type: Application
    Filed: April 28, 2011
    Publication date: May 23, 2013
    Applicant: Gachon University of Industry-Academic Cooperation Foundation
    Inventors: Bong Hee Lee, Kyung Hee Byun
  • Publication number: 20130129695
    Abstract: The invention provides methods for treating or inhibiting infection by Clostridium difficile in a subject in need of such treatment, comprising administering an effective amount of a compound binding to a CD3299 riboswitch, as well as assays for identifying compounds useful in such treatment, and the use of particular compounds in such treatment.
    Type: Application
    Filed: February 4, 2011
    Publication date: May 23, 2013
    Inventor: Kenneth Blount
  • Publication number: 20130115192
    Abstract: This application provides nanoparticles and methods of making nanoparticles using pre-functionalized poly(ethylene glycol)(also referred to as PEG) as a macroinitiator for the synthesis of diblock copolymers. Ring opening polymerization yields the desired poly(ester)-poly(ethylene glycol)-targeting agent polymer that is used to impart targeting capability to therapeutic nanoparticles. This “polymerization from” approach typically employs precursors of the targeting agent wherein the reactivity of functional groups of the targeting agent is masked using protecting groups. Also described is a “coupling to” that utilized the poly(ethylene glycol)-targeting agent conjugate where the targeting agent remains in its native un-protected form. This method uses “orthogonal” chemistry that exhibit no cross reactivity towards functional groups typically found within targeting agents of interest.
    Type: Application
    Filed: November 2, 2012
    Publication date: May 9, 2013
    Applicant: BIND BIOSCIENCES, INC
    Inventor: BIND BIOSCIENCES, INC
  • Publication number: 20130065818
    Abstract: The present invention discloses ophthalmic and otic compositions of facially amphiphilic antimicrobial polymers and oligomers and their uses, including their use in methods for treating and preventing ophthalmic infections and otic infections in humans and animals.
    Type: Application
    Filed: October 26, 2012
    Publication date: March 14, 2013
    Applicant: POLYMEDIX
    Inventor: PolyMedix
  • Publication number: 20130058983
    Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections.
    Type: Application
    Filed: August 3, 2012
    Publication date: March 7, 2013
    Inventor: Brett Hugh James Baker
  • Publication number: 20130045265
    Abstract: The invention discussed is a durable Antimicrobial Strap made using a polymer material, including plastics or vinyl, or a combination thereof, which have been enhanced through the integration of antimicrobial material adapted to kill microbes. The Antimicrobial Strap may be used in applications including but not limited to gait belts, helmet harness, and seat belts in child safety seats where the strap controls the level of cross-contamination by killing unwanted microbes that contact the strap and thereby, prevents the spread of disease and infections.
    Type: Application
    Filed: August 15, 2012
    Publication date: February 21, 2013
    Inventor: Barry Glenn Chapman
  • Publication number: 20130022661
    Abstract: A bio-remodable augmentation device including an implantable member configured for maintaining space in a bone defect. The implantable member is formed from a bio-remodable composite having structural properties so as to aid in the generation of new bone tissue and eventually be reabsorbed in the newly formed bone tissue. This structural and bio-remodable implant reduces, if not eliminates, the need to remove the implantable member from the patient once new bone tissue is formed. A kit including the implantable devices and bone growth material is disclosed. Methods of use are also disclosed.
    Type: Application
    Filed: July 21, 2011
    Publication date: January 24, 2013
    Applicant: Warsaw Orthopedic, Inc.
    Inventor: William F. McKay
  • Publication number: 20120329760
    Abstract: Methods of identifying a subject having a urinary tract infection using RNase 7 are described. The methods include providing a test sample of urine from the subject, determining the level of RNase 7 in the test sample, and then comparing the level of RNase 7 in the test sample to the level of RNase 7 in a control. A higher level of RNase 7 in the test sample indicates that the subject has an acute urinary tract infection, whereas a lower level of RNase 7 in the test sample indicates that the subject only has a chronic urinary tract infection.
    Type: Application
    Filed: April 19, 2012
    Publication date: December 27, 2012
    Applicant: NATIONWIDE CHILDREN'S HOSPITAL, INC.
    Inventors: David Hains, Andrew Lawrence Schwaderer, John David Spenser
  • Publication number: 20120232047
    Abstract: The present invention relates to compounds of formula I and to compounds of formula II wherein the substituents have various meanings. These compounds are useful as beta lactamase inhibitors.
    Type: Application
    Filed: August 12, 2010
    Publication date: September 13, 2012
    Applicant: NABRIVA THERAPEUTICS AG
    Inventor: Atchyuta Rama Chandra Murty Bulusu
  • Publication number: 20120214781
    Abstract: The present invention relates to an antibacterial food composition comprising a Propolis extract and a Vaccinium macrocarpon cranberry extract.
    Type: Application
    Filed: April 1, 2010
    Publication date: August 23, 2012
    Inventor: Loïc Renard
  • Patent number: 8231871
    Abstract: The invention relates to medicine and the chemical and pharmaceutical industry, in particular to antibiotic preparative forms. The inventive antimicrobial composition contains antibiotic selected from a group of lincosamides, broad-spectrum penicillins, cephalosporins, macrolides, tetracyclines, and lactulose at the active component ratio of 1:1-1:100. The mean particle size of lactulose ranges from 100 nm to 200 ?m. Said composition is embeddable in a solid state and in the form of a syrup or a suspension. When applicable, pharmaceutically acceptable excipients are added into the composition in such a way that it takes a form acceptable for peroral administration.
    Type: Grant
    Filed: August 25, 2005
    Date of Patent: July 31, 2012
    Inventors: Nikolai Alexandrovich Kiselev, Dmitry Sergeevich Chicherin
  • Patent number: 8222416
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: July 17, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Steven Joseph Berthel, Li Chen, Wendy Lea Corbett, Lichun Feng, Nancy-Ellen Haynes, Robert Francis Kester, Sung-Sau So, Jefferson Wright Tilley